Your browser doesn't support javascript.
loading
Cell-free DNA levels are increased in acute graft-versus-host disease.
Kroeze, Anna; Cornelissen, Anne S; Pascutti, M Fernanda; Verheij, Myrddin; Bulder, Ingrid; Klarenbeek, Sjoerd; Ait Soussan, Aicha; Hazenberg, Mette D; Nur, Erfan; van der Schoot, C Ellen; Voermans, Carlijn; Zeerleder, Sacha S.
Afiliação
  • Kroeze A; Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands.
  • Cornelissen AS; Department of Hematopoiesis, Sanquin Research, Amsterdam, The Netherlands.
  • Pascutti MF; Department of Hematopoiesis, Sanquin Research, Amsterdam, The Netherlands.
  • Verheij M; Department of Hematopoiesis, Sanquin Research, Amsterdam, The Netherlands.
  • Bulder I; Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands.
  • Klarenbeek S; Department of Hematopoiesis, Sanquin Research, Amsterdam, The Netherlands.
  • Ait Soussan A; Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands.
  • Hazenberg MD; Department of Hematopoiesis, Sanquin Research, Amsterdam, The Netherlands.
  • Nur E; Experimental Animal Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van der Schoot CE; Department of Experimental Immunohematology, Sanquin Research, Amsterdam, The Netherlands.
  • Voermans C; Department of Hematology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands.
  • Zeerleder SS; Department of Hematology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands.
Eur J Haematol ; 109(3): 271-281, 2022 Sep.
Article em En | MEDLINE | ID: mdl-35617105
ABSTRACT

BACKGROUND:

Cell-free DNA (cfDNA) and nucleosomes, consisting of cfDNA and histones, are markers of cell activation and damage. In systemic inflammation these markers predict severity and fatality. However, the role of cfDNA in acute Graft-versus-Host Disease (aGvHD), a major complication of allogeneic hematopoietic stem cell transplantation (HSCT), is unknown.

OBJECTIVE:

The aim of this study is to investigate the role of cfDNA as a marker of aGvHD.

METHODS:

We followed nucleosome levels in 37 allogeneic HSCT patients and an established xenotransplantation mouse model. We determined the origin of cfDNA with a species-specific polymerase chain reaction.

RESULTS:

In the plasma of aGvHD patients, nucleosome levels significantly increased around the time of aGvHD diagnosis compared to pretransplant, concurrently with a significant increase of known aGvHD markers ST2 and REG3α. In mice, we confirmed that nucleosomes were elevated during clinically detectable aGvHD. We found cfDNA to be mainly of human origin and to a lesser extent of mouse origin, indicating that cfDNA is released by (proliferating) human xeno-reactive PBMC and damaged mouse cells.

CONCLUSION:

We show increased cfDNA both in an aGvHD mouse model and in aGvHD patients. We also demonstrate that donor hematopoietic cells and to a lesser degree (damaged) host cells are the cellular source of cfDNA in aGvHD. We propose that nucleosomes and cfDNA might be an additive marker for aGvHD.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Ácidos Nucleicos Livres / Doença Enxerto-Hospedeiro Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Eur J Haematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Ácidos Nucleicos Livres / Doença Enxerto-Hospedeiro Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Eur J Haematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda